Contraindicated (one)bortezomib will boost the degree or influence of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or average CYP2C19 inhibitors may possibly increase mavacamten systemic exposure, resulting in heart failure as a consequence of systolic dysfunction. Explain to your medical professional For anyone who is pregnant or approach https://johnb322myi4.bloggadores.com/profile